Yokoyama K, Takashima T, Nozaki M, Kurokawa A, Matsumoto K
Gan To Kagaku Ryoho. 1985 Feb;12(2):265-9.
Effects of BAI therapy on 86 cases of lung cancer were evaluated in three groups: single-use of MMC group after intravenous PEP administration (PEP (iv).MMC group), PEP and MMC combination use group (PEP + MMC group) and single use of MMC group. Tumor regression rate determined by chest X-ray film 2 or 3 weeks after BAI was highest in the PEP (iv).MMC group followed by the PEP + MMC and MMC group. Cavity formation was more typical in the group treated with PEP + MMC. Histopathological effects were best for the PEP + MMC group followed by those of the PEP (iv).MMC and MMC group. As for side effects, pulmonary fibrosis and necrotizing bronchitis were noted in 8% of the PEP + MMC group, but side effects in the other two groups were mild. In conclusion single use of MMC after intravenous PEP administration was found to be the best way to give BAI in these three groups.
将86例肺癌患者分为三组评估支气管动脉灌注（BAI）治疗的效果：静脉注射平阳霉素（PEP）后单用丝裂霉素（MMC）组（PEP（静脉注射）.MMC组）、PEP与MMC联合使用组（PEP + MMC组）以及单用MMC组。BAI治疗后2或3周通过胸部X线片确定的肿瘤消退率在PEP（静脉注射）.MMC组最高，其次是PEP + MMC组和MMC组。PEP + MMC组的空洞形成更典型。组织病理学效果以PEP + MMC组最佳，其次是PEP（静脉注射）.MMC组和MMC组。至于副作用，PEP + MMC组8%的患者出现肺纤维化和坏死性支气管炎，但其他两组的副作用较轻。总之，在这三组中，静脉注射PEP后单用MMC被认为是进行BAI治疗的最佳方法。
